70.11
1.82%
-1.30
Cytokinetics Inc stock is currently priced at $70.11, with a 24-hour trading volume of 1.61M.
It has seen a -1.82% decreased in the last 24 hours and a -4.08% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $71.49 pivot point. If it approaches the $69.80 support level, significant changes may occur.
Cytokinetics Inc Stock (CYTK) Financials Data
Cytokinetics Inc (CYTK) Revenue 2023
CYTK reported a revenue (TTM) of $7.53 million for the quarter ending December 31, 2023, a -92.04% decline year-over-year.
Cytokinetics Inc (CYTK) Net Income 2023
CYTK net income (TTM) was -$526.24 million for the quarter ending December 31, 2023, a -35.30% decrease year-over-year.
Cytokinetics Inc (CYTK) Cash Flow 2023
CYTK recorded a free cash flow (TTM) of -$415.75 million for the quarter ending December 31, 2023, a -33.75% decrease year-over-year.
Cytokinetics Inc (CYTK) Earnings per Share 2023
CYTK earnings per share (TTM) was -$5.45 for the quarter ending December 31, 2023, a -28.24% decline year-over-year.
Cytokinetics Inc Stock (CYTK) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Malik Fady Ibraham | EVP Research & Development |
Mar 05 '24 |
Option Exercise |
6.67 |
28,604 |
190,789 |
167,577 |
Malik Fady Ibraham | EVP Research & Development |
Mar 05 '24 |
Sale |
67.56 |
32,604 |
2,202,606 |
138,973 |
HENDERSON JOHN T | Director |
Feb 14 '24 |
Option Exercise |
4.44 |
5,000 |
22,200 |
47,632 |
HENDERSON JOHN T | Director |
Feb 14 '24 |
Sale |
76.48 |
5,000 |
382,400 |
42,632 |
Blum Robert I | President & CEO |
Feb 13 '24 |
Option Exercise |
6.67 |
12,500 |
83,375 |
454,297 |
Blum Robert I | President & CEO |
Feb 13 '24 |
Sale |
76.85 |
12,500 |
960,625 |
441,797 |
Malik Fady Ibraham | EVP Research & Development |
Feb 06 '24 |
Option Exercise |
6.67 |
28,605 |
190,795 |
175,578 |
Malik Fady Ibraham | EVP Research & Development |
Feb 06 '24 |
Sale |
79.30 |
32,605 |
2,585,496 |
142,973 |
Blum Robert I | President & CEO |
Jan 31 '24 |
Option Exercise |
6.67 |
12,500 |
83,375 |
454,297 |
Blum Robert I | President & CEO |
Jan 31 '24 |
Sale |
79.57 |
12,500 |
994,625 |
441,797 |
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
GlobeNewswire Inc.
2 Incredible Growth Stocks to Buy Right Now
The Motley Fool
Cytokinetics to Participate in March Investor Conferences
GlobeNewswire Inc.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
This biotech ETF sees ‘breakout’ while U.S. small-cap technology stocks lag
MarketWatch
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
GlobeNewswire Inc.
About Cytokinetics Inc
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):